CYTOKINETICS INC 4

Director Edward M. Kaye received an equity award of 151 shares of Cytokinetics, Inc. common stock in lieu of cash compensation.

On July 15, 2026, Dr. Edward M. Kaye received a fully vested grant of 151 shares of Cytokinetics, Inc. common stock under the company's Equity in Lieu of Cash Retainer Program, effectively taking equity instead of cash compensation at a price of approximately $82.62 per share, for an implied transaction value of about $12,473. Following this award, Dr. Kaye directly owns 10,434 shares of Cytokinetics common stock, with an estimated post-transaction holding value of roughly $862,000 based on the reported transaction price.

Filing Facts

CIK

1061983

Ticker

CYTK

Form

4

Source Type

fda

Accession

0001061983-26-000081

Alert Tier

5